Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

  • Shionogi to conduct clinical trials, subsequent registration, and commercialization of olorofim for invasive aspergillosis (IA) in Europe and Asia
  • F2G to receive upfront payment of $100m and share development costs
  • F2G will also be eligible for additional regulatory and commercial milestones of up to $380m, as well as double-digit royalties on net sales

OSAKA, Japan, and MANCHESTER, UK, May 16, 2022 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and F2G Ltd.(Head Office: Manchester, UK; CEO: Francesco Maria Lavino; hereafter “F2G”)today announced that they have entered a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in Europe and Asia.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...